Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
Biocon on Q3 earnings performance
Description
Biosimilars business is a very capital intensive and investment intensive in terms of R&D and we will need to raise capital either through private equity or IPO, said Kiran Mazumdar Shaw, Chairperson & MD, Biocon.
More from User
03:06
Auto Expo 2020: Here's a look at MG Motor India's future ready portfolio
CNBC-TV18
02:30
Here’s what restauranteurs make of Mumbai 24x7
CNBC-TV18
04:15
Omar Abdullah's sister moves Supreme Court challenging his detention under the Public Safety Act
CNBC-TV18
04:02
Totally false that ousted CEO Neumann left with $1 Bn, says WeWork's executive chairman Marcelo Claure
CNBC-TV18
02:44
Indian ride hailing app Ola has rolled out its service in London
CNBC-TV18
02:35
London High Court to hear Mallya extradition case from tomorrow
CNBC-TV18
Related Videos
01:00
Biocon Q3 earnings: Expect a strong performance
CNBC-TV18
11:44
Earnings Edge | Syngene's Jonathan Hunt On Q3 Performance | NDTV Profit
NDTV Profit
02:07
Samsung Electronics shows better performance than expected, Q3 earnings up 17% q/q, down 56% y/y
Arirang News
03:01
Reliance Q3 Results Breaking | Mukesh Ambani | Reliance Q3 Earnings |Q3 With CNBC Awaaz | RJio Shares
DSGDIGITALNIGHT
13:54
Q2 Review: After Weak Q2, Can Biocon Bounce Back In Q3? | BQPrime
NDTV Profit
06:31
Biocon Q3 meets estimates, business grew by 23%
ET NOW